As market tanked globally, I think it might be one of the better times to buy mesoblast, before its FDA decision.
The inherent risk obviously is the outcome of FDA and the subsequent market traction of its product.
However, give its market cap about $1.1bn AUD, with the advance of its technlogy (compared to its global peers) with three phase-three stem-cell treatment and a web of patents. I think it can potentially rival the status of CSL, as a global biotech firm.
For the weekend, just want to share some light video material about patient review on Mesoblast treatment.
Personally, I think its science and stem-cell treatments are absolutely solid and life-saving, especially for conditions, which conventional standard of care could not treat. It would be a loss to people, if its treatment does not get FDA and other approvals to benefit more patients globally.
- Forums
- ASX - By Stock
- MSB
- Real patient review on Mesoblast treatment
Real patient review on Mesoblast treatment
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.03 |
Change
-0.040(3.76%) |
Mkt cap ! $1.170B |
Open | High | Low | Value | Volume |
$1.07 | $1.07 | $1.01 | $13.19M | 12.81M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 61090 | $1.02 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.03 | 239558 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 61090 | 1.015 |
1 | 700 | 1.010 |
9 | 123952 | 1.005 |
34 | 516697 | 1.000 |
1 | 25000 | 0.995 |
Price($) | Vol. | No. |
---|---|---|
1.030 | 17500 | 1 |
1.035 | 54000 | 2 |
1.040 | 41250 | 2 |
1.045 | 68050 | 4 |
1.050 | 45395 | 3 |
Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online